Amgen, a global biotechnology company, has announced the appointment of Naveen Gullapalli as the Managing Director of Amgen India. In this new role, Naveen will leverage his extensive experience in global operations, digital transformation, and business innovation to lead the Hyderabad-based Amgen India Technology and Innovation Centre. His appointment marks a significant step in Amgen’s mission to advance patient care globally through the convergence of biotechnology and cutting-edge digital technologies.
Naveen Gullapalli brings a wealth of experience in driving operational excellence, business transformation, and technological innovation. Before joining Amgen, he had a distinguished career at Novartis, where he served as the head of the Global Business Solutions division. At Novartis, he managed operations across multiple corporate centers and was instrumental in driving strategic growth. His leadership skills and expertise in scaling global operations played a key role in Novartis’s success, particularly in navigating the complexities of the healthcare and pharmaceutical sectors. Naveen’s understanding of both the scientific and business aspects of the biotechnology and healthcare industries will play an essential role in strengthening Amgen’s position in India.
Naveen’s extensive background also includes leadership roles at Thomson Reuters, where he further honed his skills in scaling global operations and spearheading business transformation initiatives. His tenure at Thomson Reuters, one of the world’s leading sources of intelligent information for businesses and professionals, added to his diverse expertise, particularly in leveraging technology to drive business growth and efficiency. This diverse experience in both healthcare and technology companies positions Naveen to lead Amgen India’s innovation strategies with a unique perspective and focus.
In his role as Managing Director, Naveen Gullapalli will focus on driving innovation and technology solutions that enhance patient care worldwide. His leadership will be pivotal in advancing Amgen’s technology-driven efforts to develop and deliver innovative biotech therapies that address unmet medical needs. The convergence of biotechnology, data science, and artificial intelligence (AI) will be at the core of his strategic initiatives. Naveen’s deep understanding of digital technologies, including AI and data science, will help Amgen India harness the full potential of emerging technologies to accelerate drug discovery, improve treatment outcomes, and optimize healthcare delivery systems.
The Amgen India Technology and Innovation Centre, which Naveen will oversee, is central to the company’s commitment to advancing cutting-edge research and delivering impactful healthcare solutions. The centre’s focus on biotechnology and digital innovation is expected to result in the development of novel technologies that will improve the efficiency and accessibility of healthcare solutions, not just in India, but also across the globe. By focusing on AI, machine learning, and advanced data analytics, Naveen and his team aim to transform how Amgen develops, tests, and delivers biopharmaceutical products.
